| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6602911 | ALLERGAN | Methods of treating fibromyalgia |
Jan, 2023
(8 months ago) | |
| US7994220 | ALLERGAN | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(5 years from now) | |
Savella is owned by Allergan.
Savella contains Milnacipran Hydrochloride.
Savella has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Savella are:
- US6602911
Savella was authorised for market use on 14 January, 2009.
Savella is available in tablet;oral dosage forms.
Savella can be used as management of fibromyalgia (fm), management of fibromyalgia.
The generics of Savella are possible to be released after 19 September, 2029.
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
SAVELLA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic